SPAULDING REHABILITATION HOSPITAL BOSTON

SRH Institutional Review Board
APPROVAL Effective Date
9/30/2014

Huperzine A for the Treatment of Cognitive, Mood, and Functional Deficits after Moderate and Severe Traumatic Brain Injury Study

Purpose: To determine whether a dietary supplement, Huperzine A, has an effect on learning and memory after a moderate to severe traumatic brain Injury (TBI)

To Qualify: Men & Women, 18-65 years old, who have sustained a moderate to severe brain injury less than 1 year ago. Subjects must have significant cognitive complaints.

Length of Study: 52 Weeks

Study Visits: **7 Visits Total**

- Screening Visit
- Baseline Visits
- Study Visit 2 – Week 6
- Study Visit 3 – Week 12
- Study Visit 4 – Week 13
- Study Visit 5 – Week 24
- Study Visit 6 – Week 52

Procedures:

- Physical exam and blood draws
- Neuropsychological & Cognitive Testing
- Neurophysiological testing – Eye tracking, EEG & TMS
- Randomization to receive Huperzine A or placebo for 12 weeks

Exclusions: Subjects will be excluded if**:**

- Younger than 18 or older than 65 years of age
- TBI occurred more than 1 year ago
- Smoker
- History of pre-injury epilepsy
- Some medications are exclusions, including oral contraceptives

Stipend:

- $25 stipend & parking for completing the Screening Visit
- If you qualify for the study at Screening – receive an additional $425 stipend and parking for study completion